The potential protective role of corticosteroid therapy in patients with asthma and COPD against COVID-19

被引：8
作者：
Furci F. [1 ]
Caminati M. [2 ]
Senna G. [2 ,3 ]
Gangemi S. [1 ]
机构：
[1] School and Operative Unit of Allergy and Clinical Immunology, Policlinico “G. Martino”, Department of Clinical and Experimental Medicine, University of Messina, Messina
[2] Department of Medicine, University of Verona and Verona University Hospital, Verona
[3] Asthma Centre and Allergy Unit, University of Verona and Verona University Hospital, Verona
来源：
Clinical and Molecular Allergy | / 19卷 / 1期
关键词：
Asthma; COPD; Corticosteroids; COVID-19; Hospitalization; Pulmonary diseases;
D O I：
10.1186/s12948-021-00159-4
中图分类号：
学科分类号：
摘要：
Background: The observation of patients hospitalized for coronavirus disease (COVID-19) led us to note a lower prevalence of patients affected by chronic respiratory disease, in particular asthmatic patients, compared to the general population. Therefore, the aim of this paper is to evaluate the possible protective role of corticosteroid therapy in patients with chronic lung disease, regarding the risk of contracting severe COVID-19. Main body: SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptors to enter the cells. Considering the high number of these receptors in patients affected by asthma and chronic obstructive pulmonary disease (COPD), the evidence that these patients do not have a high risk of hospitalization for COVID-19 needs further study to understand what the possible protective “factors” are in these patients. In particular, the finding in some studies of reduced coronavirus replication in cell lines treated with steroids, molecules commonly used for treating chronic lung diseases, needs further attention. Short conclusion: The hypothesis that corticosteroids, commonly used in treating airways diseases, might modify the severity of SARS-CoV-2 disease has become a key point and a possible predictive factor of a positive outcome of COVID-19 in patients treated everyday with these molecules. © 2021, The Author(s).
引用
收藏
相关论文
共 33 条
[1]  
Rogliani P., Lauro D., Di Daniele N., Chetta A., Calzetta L., Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?, Expert Rev Respir Med, 15, pp. 561-568, (2021)
[2]  
Li X., Xu S., Yu M., Wang K., Tao Y., Zhou Y., Et al., Risk factors for severity and mortality in adult COVID-19 in patients in Wuhan, J Allergy Clin Immunol, 146, pp. 110-118, (2020)
[3]  
Caminati M., Lombardi C., Micheletto C., Roca E., Bigni B., Furci F., Et al., Asthmatic patients in COVID-19 outbreak: few cases despite many cases, J Allergy Clin Immunol, 146, pp. 541-542, (2020)
[4]  
Jeon S., Ko M., Lee J., Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs, Antimicrob Agents Chemother, 64, pp. 00819-00820, (2020)
[5]  
Yamaya M., Nishimura H., Deng X., Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells, Respir Investig, 58, pp. 155-168, (2020)
[6]  
Halpin D.M.G., Singh D., Hadfield R.M., Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective, Eur Respir J, 55, (2020)
[7]  
Yang M., Zhang Y., Chen H., Lin J., Zeng J., Xu Z., Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis, Infection, 47, pp. 377-385, (2019)
[8]  
Maes T., Bracke K., Brusselle G.G., COVID-19, asthma, and inhaled corticosteroids: another beneficial effect of inhaled corticosteroids?, Am J Respir Crit Care Med, 202, pp. 8-10, (2020)
[9]  
Oliver B.C.G., Robinson P., Peters M., Black J., Viral infections and asthma: an inflammatory interface?, Eur Respir J, 44, pp. 1666-1681, (2014)
[10]  
Aveyard P., Gao M., Lindson N., Hartmann-Boyce J., Watkinson P., Young D., Et al., Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study, Lancet Respir Med, 9, pp. 909-923, (2021)
1234